{"DataElement":{"publicId":"6032878","version":"1","preferredName":"Disease or Disorder Computed Tomography Best Radiologic Response Outcome of Therapy Lugano Lymphoma Response Classification Type","preferredDefinition":"A description of the best radiologic lugano lymphoma response to therapy by computed tomography.","longName":"6032871v1.0:6042897v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"6032871","version":"1","preferredName":"Disease or Disorder Computed Tomography Best Radiologic Response Outcome of Therapy","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis._Having the most positive qualities._An evaluation of the radiologic response of the disease to the therapy._The result of therapy for a given disease or condition in a patient or group of patients.","longName":"2404658v1.0:6032869v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6032869","version":"1","preferredName":"Computed Tomography Best Radiologic Response Outcome of Therapy","preferredDefinition":"A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.:Having the most positive qualities.:An evaluation of the radiologic response of the disease to the therapy.:The result of therapy for a given disease or condition in a patient or group of patients.","longName":"C17204:C25432:C123627:C18919","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Computed Tomography","conceptCode":"C17204","definition":"A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Best","conceptCode":"C25432","definition":"Having the most positive qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Radiologic Response","conceptCode":"C123627","definition":"An evaluation of the radiologic response of the disease to the therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome of Therapy","conceptCode":"C18919","definition":"The result of therapy for a given disease or condition in a patient or group of patients.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F0B6FEE-59D8-223A-E053-F662850ADC93","latestVersionIndicator":"Yes","beginDate":"2017-11-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-28","modifiedBy":"ONEDATA","dateModified":"2017-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F0B6FEE-59E9-223A-E053-F662850ADC93","latestVersionIndicator":"Yes","beginDate":"2017-11-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-28","modifiedBy":"NYCHM","dateModified":"2018-02-12","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6042897","version":"1","preferredName":"Computed Tomography Lugano Lymphoma Response Classification Type","preferredDefinition":"A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis._A lymphoma response criteria system developed at the 11th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, June 2011._Something distinguishable as an identifiable class based on common qualities.","longName":"6042897v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Continued complete remission (CCR)","valueDescription":"Continued Lugano Lymphoma Response Classification Complete Remission by CT","ValueMeaning":{"publicId":"6042908","version":"1","preferredName":"Continued Lugano Lymphoma Response Classification Complete Remission by CT","longName":"6042908","preferredDefinition":"Remain in force or carry on without letup; keep or maintain in unaltered condition; exist in time or space without stop or interruption.: Target nodes/nodal masses must regress to less than or equal to 1.5 cm in the longest transverse diameter. Complete disappearance of radiologic evidence of disease. No extralymphatic sites of disease. Organ enlargement regress to normal. Bone marrow normal by morphology; if indeterminate, IHC negative.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Continue","conceptCode":"C53279","definition":"Remain in force or carry on without letup; keep or maintain in unaltered condition; exist in time or space without stop or interruption.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lugano Lymphoma Response Classification Complete Remission by CT","conceptCode":"C142791","definition":"Target nodes/nodal masses must regress to less than or equal to 1.5 cm in the longest transverse diameter. Complete disappearance of radiologic evidence of disease. No extralymphatic sites of disease. Organ enlargement regress to normal. Bone marrow normal by morphology; if indeterminate, IHC negative.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6052A3B4-6532-353F-E053-F662850A5B9A","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6052A3B4-654B-353F-E053-F662850A5B9A","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"ONEDATA","dateModified":"2017-12-14","deletedIndicator":"No"},{"value":"No response (NR) / Stable disease (SD)","valueDescription":"Lugano Lymphoma Response Classification No Response/Stable Disease by CT","ValueMeaning":{"publicId":"6043206","version":"1","preferredName":"Lugano Lymphoma Response Classification No Response/Stable Disease by CT","longName":"6043206","preferredDefinition":"Less than 50 percent decrease from baseline in  the sum of the product of the perpendicular diameters of up to 6 dominant, measurable nodes and extranodal sites; no criteria for progressive disease are met.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lugano Lymphoma Response Classification No Response/Stable Disease by CT","conceptCode":"C142793","definition":"Less than 50 percent decrease from baseline in  the sum of the product of the perpendicular diameters of up to 6 dominant, measurable nodes and extranodal sites; no criteria for progressive disease are met.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"609D7F30-9414-4A1A-E053-F662850A9F7C","latestVersionIndicator":"Yes","beginDate":"2017-12-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"60A09B4A-1CFC-6273-E053-F662850ACD09","beginDate":"2017-12-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-18","modifiedBy":"ONEDATA","dateModified":"2017-12-18","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2572577","version":"1","preferredName":"Unknown","longName":"2572577","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E88E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-12-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-12-30","modifiedBy":"COLBERTM","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6051E120-74D7-5D78-E053-F662850AD4D8","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"ONEDATA","dateModified":"2017-12-14","deletedIndicator":"No"},{"value":"Not assessed","valueDescription":"NOT ASSESSED","ValueMeaning":{"publicId":"2559594","version":"1","preferredName":"NOT ASSESSED","longName":"2559594","preferredDefinition":"Indicates that an assessment was not performed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Assessed","conceptCode":"C139527","definition":"Indicates that an assessment was not performed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B5D7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-02-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6051E120-74E1-5D78-E053-F662850AD4D8","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"ONEDATA","dateModified":"2017-12-14","deletedIndicator":"No"},{"value":"Progressive disease (PD)","valueDescription":"Lugano Lymphoma Response Classification Progressive Disease by CT","ValueMeaning":{"publicId":"6042898","version":"1","preferredName":"Lugano Lymphoma Response Classification Progressive Disease by CT","longName":"6042898","preferredDefinition":"Progressive disease is assigned with at least one of the following: an individual node must be abnormal with the longest transverse diameter greater than 1.5 cm or an increase by greater than or equal to 50 percent from the product of the perpendicular diameter nadir; an increase in the longest transverse diameter or shortest transverse diameter from nadir 0.5 cm for lesions less than or equal to 2 cm or 1.0 cm for lesions greater than 2 cm. New or recurrent splenomegaly; a new node >1.5 cm in any axis; new or recurrent bone marrow involvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lugano Lymphoma Response Classification Progressive Disease by CT","conceptCode":"C142794","definition":"Progressive disease is assigned with at least one of the following: an individual node must be abnormal with the longest transverse diameter greater than 1.5 cm or an increase by greater than or equal to 50 percent from the product of the perpendicular diameter nadir; an increase in the longest transverse diameter or shortest transverse diameter from nadir 0.5 cm for lesions less than or equal to 2 cm or 1.0 cm for lesions greater than 2 cm. New or recurrent splenomegaly; a new node >1.5 cm in any axis; new or recurrent bone marrow involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6051E120-74ED-5D78-E053-F662850AD4D8","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6051E120-7506-5D78-E053-F662850AD4D8","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"ONEDATA","dateModified":"2017-12-14","deletedIndicator":"No"},{"value":"Complete remission (CR)","valueDescription":"Lugano Lymphoma Response Classification Complete Remission by CT","ValueMeaning":{"publicId":"6042899","version":"1","preferredName":"Lugano Lymphoma Response Classification Complete Remission by CT","longName":"6042899","preferredDefinition":"Target nodes/nodal masses must regress to less than or equal to 1.5 cm in the longest transverse diameter. Complete disappearance of radiologic evidence of disease. No extralymphatic sites of disease. Organ enlargement regress to normal. Bone marrow normal by morphology; if indeterminate, IHC negative.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lugano Lymphoma Response Classification Complete Remission by CT","conceptCode":"C142791","definition":"Target nodes/nodal masses must regress to less than or equal to 1.5 cm in the longest transverse diameter. Complete disappearance of radiologic evidence of disease. No extralymphatic sites of disease. Organ enlargement regress to normal. Bone marrow normal by morphology; if indeterminate, IHC negative.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6051E120-7512-5D78-E053-F662850AD4D8","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6051E120-752B-5D78-E053-F662850AD4D8","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"ONEDATA","dateModified":"2017-12-14","deletedIndicator":"No"},{"value":"Partial remission (PR)","valueDescription":"Lugano Lymphoma Response Classification Partial Remission by CT","ValueMeaning":{"publicId":"6042907","version":"1","preferredName":"Lugano Lymphoma Response Classification Partial Remission by CT","longName":"6042907","preferredDefinition":"For multiple lesions, greater than or equal to 50 percent decrease in the sum of the product of the perpendicular diameters of up to six target measurable nodes and extranodal sites. If only a single lesion is present, greater than or equal to 50 percent decrease in the cross product of the longest transverse diameter and perpendicular diameter. Spleen must have regressed by >50% in length beyond normal to the definition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lugano Lymphoma Response Classification Partial Remission by CT","conceptCode":"C142792","definition":"For multiple lesions, greater than or equal to 50 percent decrease in the sum of the product of the perpendicular diameters of up to six target measurable nodes and extranodal sites. If only a single lesion is present, greater than or equal to 50 percent decrease in the cross product of the longest transverse diameter and perpendicular diameter.. Spleen must have regressed by >50% in length beyond normal\" to the definition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6052A3B4-650C-353F-E053-F662850A5B9A","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"60A09B4A-1D10-6273-E053-F662850ACD09","beginDate":"2017-12-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-18","modifiedBy":"ONEDATA","dateModified":"2017-12-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6042896","version":"1","preferredName":"Computed Tomography Lugano Lymphoma Response Classification Type","preferredDefinition":"A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.:A lymphoma response criteria system developed at the 11th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, June 2011.:Something distinguishable as an identifiable class based on common qualities.","longName":"C17204:C142790:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Computed Tomography","conceptCode":"C17204","definition":"A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Lugano Lymphoma Response Classification","conceptCode":"C142790","definition":"A lymphoma response criteria system developed at the 11th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, June 2011.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6051E120-74B0-5D78-E053-F662850AD4D8","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"ONEDATA","dateModified":"2017-12-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6051E120-74C1-5D78-E053-F662850AD4D8","latestVersionIndicator":"Yes","beginDate":"2017-12-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-14","modifiedBy":"COOPERM","dateModified":"2021-01-22","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"LYMpre_therapy_multi_lym_br_line_by_ct","type":"NMDP_FN","context":"NHLBI"},{"name":"LYMpost_brs_lym_br_by_ct","type":"NMDP_FN","context":"NHLBI"},{"name":"LYMpost_OT_lym_br_line_by_ct","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the best response to HCT or cellular therapy by CT (radiographic) criteria?","type":"Alternate Question Text","description":"What was the best response to HCT or cellular therapy by CT (radiographic) criteria?","url":null,"context":"NHLBI"},{"name":"What was the best response to HCT or cellular therapy since the date of the last report by CT (radiographic) criteria?","type":"Alternate Question Text","description":"What was the best response to HCT or cellular therapy since the date of the last report by CT (radiographic) criteria?","url":null,"context":"NHLBI"},{"name":"What was the best response to HCT or cellular therapy since the date of the last report?","type":"Alternate Question Text","description":"What was the best response to HCT or cellular therapy since the date of the last report?","url":null,"context":"NHLBI"},{"name":"What was the best response by CT (radiographic) criteria to HCT or cellular therapy since the date of the last report?","type":"Alternate Question Text","description":"What was the best response by CT (radiographic) criteria to HCT or cellular therapy since the date of the last report?","url":null,"context":"NHLBI"},{"name":"What was the best radiologic","type":"Preferred Question Text","description":"What was the best radiologic lugano lymphoma response to therapy by computed tomography?","url":null,"context":"NHLBI"},{"name":"Best response to line of therapy by CT (radiographic) criteria","type":"Alternate Question Text","description":"Best response to line of therapy by CT (radiographic) criteria","url":null,"context":"NHLBI"},{"name":"Best response to line of therapy by CT (radiographic) criteria","type":"Application Standard Question Text","description":"Best response to line of therapy by CT (radiographic) criteria","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F0B9D3A-53BC-439D-E053-F662850A3D10","latestVersionIndicator":"Yes","beginDate":"2017-11-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-28","modifiedBy":"NYCHM","dateModified":"2018-02-12","changeDescription":".; System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}